Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

ACCURATE determination of HER-2 status in breast cancer is essential for guiding targeted therapy and improving clinical ...

Doctors use three markers to help define breast cancers and guide treatment. One of those is the HER2 protein. The other two are hormone receptors (HR). When a cancer has none of these ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

Factors impacting treatment with a CDK4/6i in first line metastatic HR+/HER2- breast cancer patients. Estimation of the effect of the characteristics under study on the likelihood of a high initial CA ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...

Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh ...

HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

I think in HER2+ breast cancer, it's much easier to do ... for a second opinion because they had had a circulating tumor marker, whether it was CEA, CA 15-3, or CA 27-29, that was above normal.

The phase 3 SERENA-6 trial shows that ctDNA-guided early treatment switch to camizestrant plus a CDK4/6 inhibitor in HR+, ...